Trial Outcomes & Findings for Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA (NCT NCT00458406)

NCT ID: NCT00458406

Last Updated: 2019-10-02

Results Overview

The number of minutes of use per night at month 1.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

60 participants

Primary outcome timeframe

1 month

Results posted on

2019-10-02

Participant Flow

N=60 families were enrolled; N=4 of these were excluded due to various medical conditions. Of the remaining N=56, N=43 were enrolled into the Bi-Flex arm and N=13 were enrolled into the CPAP arm.

Sixty-nine consecutive families were approached for the study. Nine families declined the study. N=60 families were enrolled; N=4 of these were excluded due to various medical conditions. Of the remaining N=56, N=43 were enrolled into the Bi-Flex arm and N=13 were enrolled into the CPAP arm.

Participant milestones

Participant milestones
Measure
Bi-Flex
Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy. In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea were randomized Bi-Flex or CPAP, and a repeat polysomnography was performed on pressure at 3 months. Of the N=56 assessed subjects, N=43 were enrolled into the Bi-Flex arm.
CPAP
Subjects randomized to this arm will undergo a clinical CPAP titration sleep study. Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy. In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea were randomized Bi-Flex or CPAP, and a repeat polysomnography was performed on pressure at 3 months. Of the N=56 assessed subjects, N=13 were enrolled into the CPAP arm.
Month 1
STARTED
43
13
Month 1
COMPLETED
43
13
Month 1
NOT COMPLETED
0
0
Month 3
STARTED
43
13
Month 3
COMPLETED
43
13
Month 3
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Bi-Flex
n=43 Participants
Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study.
CPAP
n=13 Participants
Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.
Total
n=56 Participants
Total of all reporting groups
Age, Categorical
<=18 years
43 Participants
n=5 Participants
13 Participants
n=7 Participants
56 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Continuous
12 years
STANDARD_DEVIATION 4 • n=5 Participants
12 years
STANDARD_DEVIATION 4 • n=7 Participants
12 years
STANDARD_DEVIATION 4 • n=5 Participants
Sex: Female, Male
Female
15 Participants
n=5 Participants
3 Participants
n=7 Participants
18 Participants
n=5 Participants
Sex: Female, Male
Male
28 Participants
n=5 Participants
10 Participants
n=7 Participants
38 Participants
n=5 Participants
Region of Enrollment
United States
43 participants
n=5 Participants
13 participants
n=7 Participants
56 participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 month

Population: The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.

The number of minutes of use per night at month 1.

Outcome measures

Outcome measures
Measure
Bi-Flex
n=43 Participants
Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
CPAP
n=13 Participants
Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy.
Minutes of Use Per Night at Month 1
185 minutes
Standard Deviation 165
201 minutes
Standard Deviation 135

PRIMARY outcome

Timeframe: 3 Months

Population: The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.

The number of minutes of use per night at Month 3.

Outcome measures

Outcome measures
Measure
Bi-Flex
n=43 Participants
Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
CPAP
n=13 Participants
Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy.
Minutes of Use Per Night at Month 3
183 minutes
Standard Deviation 169
125 minutes
Standard Deviation 165

PRIMARY outcome

Timeframe: month 1, month 3

minutes of use per night at Month 3 minus minutes of use per night at Month 1

Outcome measures

Outcome measures
Measure
Bi-Flex
n=43 Participants
Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
CPAP
n=13 Participants
Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy.
Change in Minutes of Use Per Night From Month 1 to Month 3
-11.1 minutes
Standard Deviation 130.6
-76.2 minutes
Standard Deviation 116.6

SECONDARY outcome

Timeframe: 3 months

Population: Power calculation: The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.

Number of drop-outs included subjects in which investigators were unable to obtain a final download from the device.

Outcome measures

Outcome measures
Measure
Bi-Flex
n=43 Participants
Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
CPAP
n=13 Participants
Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy.
Drop Out Rate
1 participants
1 participants

SECONDARY outcome

Timeframe: 3 months

Population: The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.

Change in Apnea Hypopnea Index from Month 1 to Month 3. AHI at Month 3 minus AHI at Month 1.

Outcome measures

Outcome measures
Measure
Bi-Flex
n=43 Participants
Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
CPAP
n=13 Participants
Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy.
Change in Apnea Hypopnea Index (AHI; Number of Apneas and Hypopneas Per Hour of Sleep) From Month 1 to Month 3
-8.8 Apneas and Hypopneas/hr sleep
Interval -62.1 to 5.1
-13.7 Apneas and Hypopneas/hr sleep
Interval -42.8 to 6.4

SECONDARY outcome

Timeframe: 3 months

Population: The data for BiFlex and CPAP arms are not available for this Outcome Measure since the original PI for the study is deceased. Limited data are available for the study results

Polysomnographic measurements of sleep quality using the OSA 18 score at 3 months

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 3 months

Change in the Epworth Sleepiness Scale (ESS) score from Month 1 to Month 3: (Score at Month 3 minus Score at Month 1). The ESS measures daytime sleepiness in certain situations e.g. sitting/reading, watching television, sitting inactive in public, as a passenger in a car for an hour without a break, lying down to rest in the afternoon when circumstances permit, sitting/talking with someone, sitting quietly after lunch, or in a car, while stopped for a few minutes in traffic. The scale ranges from a minimum of zero to 24, with higher scores indicating greater daytime sleepiness.

Outcome measures

Outcome measures
Measure
Bi-Flex
n=43 Participants
Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
CPAP
n=13 Participants
Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy.
Change in ESS From Month 1 to Month 3
-4.5 units on a scale
Standard Deviation 4.0
-2.3 units on a scale
Standard Deviation 4.8

SECONDARY outcome

Timeframe: 3 months

Change in the total Nasal Obstruction Symptom Evaluation (NOSE) scale score (Score at Month 3 minus Score at Month 1). This scale evaluates the severity of nasal obstructive symptoms. The scale ranges from 0-20, with a higher score indicating more nasal obstruction.

Outcome measures

Outcome measures
Measure
Bi-Flex
n=43 Participants
Subjects in this arm underwent bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
CPAP
n=13 Participants
Subjects in this arm underwent standard continuous positive airway pressure (CPAP) therapy.
Change in NOSE Scale Score From Month 1 to Month 3
-1.6 units on a scale
Standard Deviation 6.8
-5.7 units on a scale
Standard Deviation 5.9

SECONDARY outcome

Timeframe: 3 months

Population: The data for BiFlex and CPAP arms are not available for this Outcome Measure since the original PI for the study is deceased. Limited data are available for the study results

Change in quality of life from baseline to 3 months

Outcome measures

Outcome data not reported

Adverse Events

Bi-Flex

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

CPAP

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Paul R. Gallagher, MA

CTRC, Children's Hospital of Philadelphia

Phone: 215-590-2739

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place